ABSTRACT
Background Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to understand the impact of COVID-19 on new and pre-existing symptoms of MS.
Methods The COVID-19 and MS study is an ongoing community-based, prospective cohort study conducted as part of the United Kingdom MS Register. People with MS and COVID-19 were invited by email to complete a questionnaire about their MS symptoms during the infection. An MS exacerbation was defined as developing new MS symptoms and/or worsening of pre-existing MS symptoms.
Results Fifty-seven percent (230/404) of participants had an MS exacerbation during their infection; 82 developed new MS symptoms, 207 experienced worsened pre-existing MS symptoms, and 59 reported both. Disease modifying therapies (DMTs) reduced the likelihood of developing new MS symptoms during the infection (OR 0.556, 95%CI 0.316-0.978). Participants with a higher pre-COVID-19 webEDSS (web-based Expanded Disability Status Scale) score (OR 1.251, 95%CI 1.060-1.478) and longer MS duration (OR 1.042, 95%CI 1.009-1.076) were more likely to experience worsening of their pre-existing MS symptoms during the infection.
Conclusion COVID-19 infection was associated with exacerbation of MS. DMTs reduced the chance of developing new MS symptoms during the infection.
Competing Interest Statement
AG, RMM and KTD have received funding from the UK MS society. AG has received speaker honoraria from the MS Academy. RH reports no conflicts of interest. AC has received honoraria and travel support from Sanofi, up until September 2017. RD has received speaker honoraria from Biogen Idec, Teva, Neurology Academy, and Sanofi Genzyme. She has received research support from Biogen, Merck, and Celgene. MD has received personal honoraria for speaking, advisory boards, participation in research and travel expenses from Bayer, Biogen, Celgene (BMS), Merck, Mylan, Novartis, Roche, Sanofi Genzyme, Teva and TG Therapeutics. SH has received unrestricted educational grants or speaking honoraria from Biogen, Merck Serono, Novartis, Roche, and Sanofi-Aventis. OP has received honoraria and travel expenses from Biogen, Bayer, Genzyme, Merck, Novartis, Roche, and Teva. He has served on advisory boards for Biogen, Celgene, Novartis, Genzyme, Merck, and Roche. DR has received consulting fees from Bayer, Celgene, Biogen, Janssen-Cilag, MedDay, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva Neuroscience. He has received research support from Actelion, Biogen, GW Pharma, Janssen-Cilag, MedDay, Merck Serono, Mitsubishi, Novartis, Sanofi Genzyme, Teva Neuroscience, and TG Therapeutics. ET has received consulting or speaker honoraria from Roche, Novartis, and Takeda and travel expenses to attend educational meetings from Biogen, Merck, and Roche. RdN is the Chair of the NIHR Research for Patient Benefit East Midlands Research Advisory Committee. He has received funding to prepare and deliver lectures on cognitive rehabilitation in multiple sclerosis from Novartis and Biogen. RN has received support for advisory boards and travel from Novartis, Roche, and Biogen. He has received grant support from the UK MS Society. He is a member of a NICE HTA committee. NE has served as a member of advisory boards for Biogen, Merck, Novartis, and Roche. He has received grant income from the UK MS Society, MRC, PCORI and NIHR.
Clinical Trial
clinicaltrials.gov: NCT04354519
Funding Statement
The research was supported by the UK MS Society (funding reference 131).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for UKMSR studies was obtained from South West-Central Bristol Research Ethics Committee (16/SW/0194).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are stored on the UKMSR Secure e-Research Platform at Swansea University Medical School. Line level data cannot be released, but qualified researchers, subject to governance, can request access to data.
